SutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia

FOSTER CITY, Calif., March 26, 2020 -- (Healthcare Sales & Marketing Network) -- SutroVax, a biopharmaceutical company dedicated to the delivery of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious dise... Biopharmaceuticals, Venture Capital SutroVax, conjugate vaccine, vaccine
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news